Authors :
Augustine S. Samorlu
Volume/Issue :
Volume 7 - 2022, Issue 8 - August
Google Scholar :
https://bit.ly/3IIfn9N
Scribd :
https://bit.ly/3CRkV2f
DOI :
https://doi.org/10.5281/zenodo.7045400
Abstract :
An outbreak of Coronavirus disease-2019
(COVID-19), firstly reported in Wuhan, China in
December 2019, and eventually turned into pandemic, is
continuing to put a lot of burden on the health sectors
worldwide. Thus, finding a fast and effective therapy is
crucial to discontinue the current human-to-human
transmission and to treat serious cases. Several active preclinical and clinical studies are going on towards these
goals, while existing drugs are being used alone and in
combination to treat symptoms in COVID-19 patients.
Here, bearing in mind the timeline and various stages of
drug development, and considering the extremely-low
probability that any new biological target or molecule
identified as potentially relevant to the SARS-CoV-2 will
result in an approved new medicine, a brief look at those
basic studies and clinical trials of the investigational drugs
and projected success of COVID-19 therapeutics based on
the unprecedented rapidity of the processes being
witnessed were emphasized. Despite the current explosion
in such studies, from an expert opinion, it is believed that
concerted and efficient development plans may ultimately
yield a fast and effective medicine for the disease or we may
live with the disease (COVID-19).
Keywords :
SARS-Cov-2, COVID-19, Clinical Trials, Therapeutics, Drug Development
An outbreak of Coronavirus disease-2019
(COVID-19), firstly reported in Wuhan, China in
December 2019, and eventually turned into pandemic, is
continuing to put a lot of burden on the health sectors
worldwide. Thus, finding a fast and effective therapy is
crucial to discontinue the current human-to-human
transmission and to treat serious cases. Several active preclinical and clinical studies are going on towards these
goals, while existing drugs are being used alone and in
combination to treat symptoms in COVID-19 patients.
Here, bearing in mind the timeline and various stages of
drug development, and considering the extremely-low
probability that any new biological target or molecule
identified as potentially relevant to the SARS-CoV-2 will
result in an approved new medicine, a brief look at those
basic studies and clinical trials of the investigational drugs
and projected success of COVID-19 therapeutics based on
the unprecedented rapidity of the processes being
witnessed were emphasized. Despite the current explosion
in such studies, from an expert opinion, it is believed that
concerted and efficient development plans may ultimately
yield a fast and effective medicine for the disease or we may
live with the disease (COVID-19).
Keywords :
SARS-Cov-2, COVID-19, Clinical Trials, Therapeutics, Drug Development
